Effects of Somatostatin on ADPKD Heart

Key facts

Sponsor

Federico II University

Principal Investigator

eleonora riccio, md

Federico II University

Intervention

Octeotride(drug)

Enrollment

35 enrolled

Eligibility

18-80 years · All sexes

Timeline

2009

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Autosomal dominant polycystic kidney disease

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07454174
  Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease
  Richard Fatica
• RECRUITINGPHASE2NCT07161037
  Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
  Vertex Pharmaceuticals Incorporated
• RECRUITINGPHASE1NCT07228364
  Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease
  AstraZeneca
• RECRUITINGNCT06970028
  Somatosensory Phenotyping of ADPKD
  Universitaire Ziekenhuizen KU Leuven
• RECRUITINGNCT07260071
  Hypertension in Children and Young People at Risk of Autosomal Dominant Polycystic Kidney Disease
  King's College London
• ACTIVE NOT RECRUITINGNCT07016282
  Simulated and Synthetic Health Data: Improving Clinical Research on Rare Diseases. A Real-World Data Simulation of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Trials. A Retrospective, Observational Study
  Mario Negri Institute for Pharmacological Research
• RECRUITINGPHASE2NCT06902558
  A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
  AbbVie
• RECRUITINGPHASE1NCT06714006
  Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003
  PYC Therapeutics

See all trials for Autosomal dominant polycystic kidney disease →